Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maternal β-Blocker Use and Fetal Cardiac Anomalies

Maternal β-Blocker Use and Fetal Cardiac Anomalies Letters Corresponding Author: Laxmi V. Ghimire, MD, Gladstone Institute of Author Affiliations: Department of Pharmacology, Izmir Katip Celebi University Cardiovascular Disease (GICD), 1650 Owens St, San Francisco, CA 94158 School of Medicine, Izmir, Turkey (Keskin-Arslan, Akoz); Terafar-Izmir Katip (laxmivilasg@gmail.com; laxmi.ghimire@ucsf.edu). Celebi University Teratology Information, Training, and Research Center, Izmir, Turkey (Kaplan). Conflict of Interest Disclosures: None reported. Corresponding Author: Yusuf Cem Kaplan, MD, Department of Editorial Note: This letter was shown to the corresponding author of the Pharmacology, Izmir Katip Celebi University School of Medicine, Izmir Katip original article, who declined to reply on behalf of the authors. Celebi University Teratology Information, Training, and Research Center, Izmir 1. Mandalenakis Z, Rosengren A, Skoglund K, Lappas G, Eriksson P, Dellborg M. Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, Klinik Survivorship in Children and Young Adults With Congenital Heart Disease in Farmakoloji ve Toksikoloji Birimi, 35360, Karabağlar, İzmir, Türkiye Sweden. JAMA Intern Med. 2017;177(2):224-230. doi:10.1001/jamainternmed (seawise@gmail.com). .2016.7765 Conflict of Interest Disclosures: None reported. 2. Hoffman JIE, ed. The Natural and Unnatural History of Congenital Heart Disease. 1. Duan L, Ng A, Chen W, et al. β-Blocker exposure in pregnancy and risk of fetal Oxford, England: Wiley-Blackwell; 2009. cardiac anomalies. JAMA http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Maternal β-Blocker Use and Fetal Cardiac Anomalies

Loading next page...
 
/lp/american-medical-association/maternal-blocker-use-and-fetal-cardiac-anomalies-QqJuQ0Lams

References (5)

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2017.4894
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Laxmi V. Ghimire, MD, Gladstone Institute of Author Affiliations: Department of Pharmacology, Izmir Katip Celebi University Cardiovascular Disease (GICD), 1650 Owens St, San Francisco, CA 94158 School of Medicine, Izmir, Turkey (Keskin-Arslan, Akoz); Terafar-Izmir Katip (laxmivilasg@gmail.com; laxmi.ghimire@ucsf.edu). Celebi University Teratology Information, Training, and Research Center, Izmir, Turkey (Kaplan). Conflict of Interest Disclosures: None reported. Corresponding Author: Yusuf Cem Kaplan, MD, Department of Editorial Note: This letter was shown to the corresponding author of the Pharmacology, Izmir Katip Celebi University School of Medicine, Izmir Katip original article, who declined to reply on behalf of the authors. Celebi University Teratology Information, Training, and Research Center, Izmir 1. Mandalenakis Z, Rosengren A, Skoglund K, Lappas G, Eriksson P, Dellborg M. Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, Klinik Survivorship in Children and Young Adults With Congenital Heart Disease in Farmakoloji ve Toksikoloji Birimi, 35360, Karabağlar, İzmir, Türkiye Sweden. JAMA Intern Med. 2017;177(2):224-230. doi:10.1001/jamainternmed (seawise@gmail.com). .2016.7765 Conflict of Interest Disclosures: None reported. 2. Hoffman JIE, ed. The Natural and Unnatural History of Congenital Heart Disease. 1. Duan L, Ng A, Chen W, et al. β-Blocker exposure in pregnancy and risk of fetal Oxford, England: Wiley-Blackwell; 2009. cardiac anomalies. JAMA

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Nov 1, 2017

There are no references for this article.